Bridge Biotherapeutics, Boehringer Ingelheim cancel agreement to develop BBT-877 for idiopathic…
Under the License Agreement, Bridge Biotherapeutics will regain all rights to BBT-877
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.